ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2608

Subsets in Systemic Sclerosis-ILD: Working Towards Consensus-Based Definitions

David Roofeh1, Kevin Brown 2, Donald Tashkin 3, Shervin Assassi 4, Shaney Barratt 5, Elana Bernstein 6, Nitin Bhatt 7, Lorinda Chung 8, Harold Collard 9, Richard Conway 10, Paul Dellaripa 11, Christopher Denton 12, Oliver Distler 13, Robyn Domsic 14, Tracy J. Doyle 15, Puneet Garcha 16, Nishant Gupta 17, Anna Maria Hoffmann-Vold 18, Vivien Hsu 19, Francesca Ingegnoli 20, Kerri Johannson 21, Bashar Kahaleh 22, Leticia Kawano-Dourado 23, Ella Kazerooni 1, Surabhi Khanna 17, Peter Korsten 24, Celia JF Lin 25, Toby Maher 26, Stephen Mathai 27, Fernando Martinez 28, Eric Matteson 29, Vivek Nagaraja 30, Chester Oddis 31, Juan Ovalles-Bonilla 32, John Pauling 33, Ganesh Raghu 34, Ignasi Rodriguez-Pinto 35, Ivan Rosas 15, James Seibold 36, Virginia Steen 37, Vibeke Strand 38, Elizabeth Volkmann 39, Dharshan Vummidi 30, Simon Walsh 40, Donald Zoz 41, Athol Wells 42 and Dinesh Khanna 43, 1University of Michigan, Ann Arbor, 2National Jewish Health, Denver, 3University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, 4Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX, 5North Bristol NHS Trust, Bristol, England, United Kingdom, 6Columbia University, New York City, 7Ohio State University Wexner Medical Center, Columbus, 8Stanford University, Palo Alto, CA, 9University of California San Fransisco, San Fransisco, 10Blackrock Clinic, Dublin, Ireland, 11Brigham and Women's Hospital, Boston, MA, 12University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, UK, London, United Kingdom, 13Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, 14University of Pittsburgh, Pittsburgh, PA, 15Brigham and Women's Hospital, Harvard Medical School, Boston, 16Baylor Scott & White Health, Dallas, 17University of Cincinnati, Cincinnati, 18Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, 19Rutgers- RWJ Medical School, SOUTH PLAINFIELD, NJ, 20Division of Clinical Rheumatology, ASST Pini-CTO, Università degli Studi di Milano, Department of Clinical Sciences and Community Health, Milan, Italy, Milano, Italy, 21University of Calgary, Calgary, 22University of Toledo, Toledo, OH, 23University of Sao Paulo, Sao Paulo, Brazil, 24University Medical Center Göttingen, Göttingen, Germany, 25Genentech, San Fransisco, 26National Heart and Lung Institute, Imperial College London, UK and National Institute for Health Research Clinical Research Facility, Royal Brompton Hospital, London, UK, London, United Kingdom, 27John Hopkins Pulmonary and Critical Care Medicine, Baltimore, 28Will Cornell Medicine Pulmonary & Critical Care Medicine, New York, 29Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA, Rochester, 30University of Michigan, Ann Arbor, MI, 31University of Pittsburgh Medical Center, Pittsburgh, PA, 32Hospital Gregorio Marañón, Madrid, Spain, 33Department of Rheumatology, Royal National Hospital of Rheumatic Diseases, Royal United Hospitals NHS Foundation Trusts, Bath, England, United Kingdom, 34University of Washington, Seattle, USA, Seattle, 35University of Barcelona, Barcelona, Spain, 36Scleroderma Research Consultants LLC, Aiken, South Carolina, USA, Aiken, 37Georgetown University, Washington, D.C., USA, Georgetown, 38Division of Immunology/Rheumatology, Stanford University, Stanford, CA, 39University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, 40Kings College London, London, United Kingdom, 41Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA, Ridgefield, CT, 42Royal Bromptom Hospital, London, United Kingdom, 43Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: systemic sclerosis and interstitial lung disease

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Session Title: Systemic Sclerosis & Related Disorders – Clinical Poster III

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic sclerosis associated interstitial lung disease (SSc-ILD) is heterogeneous, with varying degrees of severity and risk of disease progression.  No consensus-based definitions of disease severity, progression, or risk of progression exist.  The purpose of this study was to use expert classification of real-world cases of SSc-ILD to derive definitions of SSc-ILD subsets that can be incorporated into clinical practice and trials. 

Methods: All patients included in this study met American College of Rheumatology Criteria for Systemic Sclerosis (N=80).

Patient profiles were developed from participants in the Scleroderma Lung Study-II and ILD patients seen at a Scleroderma Center. Experts in rheumatology, pulmonary medicine, radiology, and members of the OMERACT CTD-ILD Working Group 1 provided key domains to be included in profiles. These included information on demographics, disease features (limited vs. diffuse SSc, ANA status, antibody status), pulmonary function testing, patient-reported assessments, and quantitative analysis of lung involvement on high resolution computerized tomography of the chest (HRCT) for baseline profiles; and for those with follow-up data, how these measures change over time.

Eighty-three ILD experts were surveyed for classification of 80 baseline and 40 follow-up profiles.  Baseline profiles were classified based on:  1- Severity (clinical vs. subclinical) and 2- Risk of Progression (low vs. high); follow-up profiles were classified on 3- Progression over time (stable vs. progressive vs. improved).  Each profile was rated by a minimum of 4 experts; consensus on a classification was achieved with 75% concordance. For each profile, experts provided input on the top features that helped in making their classification decision.

Results: Fifty percent (N=42) of invited experts, from 10 countries, completed the survey.

Along the dimensions of severity, risk of progression, and progression, a majority of profiles achieved consensus ratings (Figure). Of those profiles achieving consensus, the majority were classified as “clinical ILD”, “low risk”, and “stable”. Table provides a ranking of the most influential features used in classification on these dimensions.

Conclusion: These data represent the first step in creating operational definitions for ILD subsets. This expert-derived classification advances the characterization of a subset of severity (clinical ILD), subsets of risk of progression (low and high risk), and a subset of progression (stable ILD).

Features used to classify profiles on severity and progression overlapped (forced vital capacity, whole lung involvement on HRCT, dyspnea ratings), whereas the risk of progression was influenced by disease duration, type of SSc, and SSc autoantibodies in addition to the measures endorsed for severity and progression.

The next steps are to reach operational definitions for those ILD subsets not yet reaching consensus (subclinical ILD, progressive ILD, improved ILD). 

REFERENCES

  1. Khanna, D. et al. J. Rheumatol. 42, 2168–2171 (2015) 

Acknowledgment: Dr. D. Khanna is funded by NIH/NIAMS K24 AR063120 and RO1 AR070470


ACR Abstract_6 1_2019 FIGURE

Figure: Percent Profiles Achieving Consensus and Distribution of Consensus Profiles by ILD Subset


ACR Abstract_6 1_2019 TABLE

Table: The Most Influential Factors Used in Classification by Dimension


Disclosure: D. Roofeh, None; K. Brown, NIH, 2, Biogen, 5, Blade, 5, Boehringer Ingelheim, 5, Galapagos, 5, Galecto, 5, Genoa, 5, Lifemax, 5, MedImmune, 5, monARC, 5, Bionetworks, 5, OSIC, 5, Pilant, 5, ProMetic, 5, Third Pole, 5, Theravance, 5, Three Lakes Partners, 5, Veracyte, 5; D. Tashkin, None; S. Assassi, Bayer, 2, Boehringer Ingelheim, 2, 5, 8, Integrity Continuing Education, 8, 9, Medscape, 8, 9, Momenta, 2; S. Barratt, None; E. Bernstein, NIH/NIAMS, 2; N. Bhatt, None; L. Chung, BMS, 6, 9, Boehrenger-Ingelheim, 5, Boehringer Ingelheim, 5, Boehringer-Ingelheim, 5, Bristol-Myers Squib, 5, Eicos, 5, 6, 9, Eicos Steering Committee, 5, Mitsubishi Tanabe, 5, Reata, 5, 6, Reata DSMB, 5, Reatta, 5; H. Collard, None; R. Conway, None; P. Dellaripa, Bristol Myers Squibb, 2, Genentech, 2, UpToDate, 7; C. Denton, Actelion, 5, Actelion Pharmaceuticals, 5, Actelion, GlaxoSmithKline, Bayer, Sanofi, lnventiva, Boehringer Ingelheim, Roche, Bristol Myers Squibb, CSL Behring, UCB, Leadiant Biosciences, 5, Bayer, 5, Boehringer Ingelheim, 5, Bristol Myers Squibb, 5, Bristol-Myers Squibb, 5, Corbus Pharmaceuticals, 5, CSL Behring, 2, 5, GlaxoSmithKline, 2, 5, Inventiva, 2, 5, Leadiant Biosciences, 2, 5, lnventiva, 5, Pfizer, 5, Roche, 5, Sanofi, 5, UCB, 5; O. Distler, A. Menarini, 5, Abbvie, Acceleron, 5, Acceleron Pharma, 5, Actelion, 2, 5, 8, Actelion Pharmaceuticals, 2, 5, 8, 9, Amgen, 5, AnaMar, 2, 5, Bayer, 2, 5, 8, 9, Biogen Idec, 2, 5, Blade Therapeutics, 5, Boehringer Ingelheim, 2, 5, 8, 9, Catenion, 5, 9, ChemomAb, 2, 5, ChemomAB, 5, CSL Behring, 5, Ergonex, 5, espeRare Foundation, 2, 5, Genentech/Roche, 2, 5, GlaxoSmithKline, 5, GSK, 2, 5, Holds Patent mir-29 for the treatment of systemic sclerosis, 9, Inventiva, 2, 5, iQvia, 5, Italfarmaco, 2, 5, Italfarmco, 5, Lilly, 2, 5, med, 5, 8, medac, 5, Medac, 2, 5, MedImmune, 2, 5, Medscape, 5, 8, 9, Menarini, 8, Mepha, 8, Mitsubishi Tanabe, 2, 5, Mitsubishi Tanabe Pharma, 2, 5, MSD, 5, 8, Novartis, 2, 5, 8, 9, Patent, 9, Patent issued, 9, Pfizer, 2, 5, 8, Pharmacyclics, 2, 5, Roche, 5, 8, 9, Sanofi, 2, 5, Sinoxa, 2, 5, Target Bio Science, 5, Target BioScience, 5, UCB, 2, 5, 9, UCB in the area of potential treatments of scleroderma and its complications, 2, 5; R. Domsic, Boehringer Ingelheim, 5, Boehringer-Ingelheim, 5, Eicos, 5, EICOS Sciences Inc, 5; T. Doyle, Bristol-Myers Squibb, 2, Genentech, 2; P. Garcha, None; N. Gupta, None; A. Hoffmann-Vold, Actelion, 5, 8, Boehringer Ingelheim, 2, 5, 8, GSK, 5, 8; V. Hsu, None; F. Ingegnoli, None; K. Johannson, None; B. Kahaleh, None; L. Kawano-Dourado, Bristol-Myers-Squibb, 2, 5, Boehringer, 8, Roche, 8; E. Kazerooni, None; S. Khanna, None; P. Korsten, None; C. Lin, Genentech, 3; T. Maher, Boehringer Ingelheim, 5, 8; S. Mathai, None; F. Martinez, None; E. Matteson, Boehringer Ingelheim, 5, Pfizer, 2, Sun Pharmaceuticals, 2; V. Nagaraja, None; C. Oddis, None; J. Ovalles-Bonilla, None; J. Pauling, Boehringer Ingelheim, 5, Chugai Roche, 9; G. Raghu, Avalyn, 9, Bellerophan, 9, BI, 5, Biogen, 9, BMS, 9, Boehringer Ingelheim, 5, Bristol-Myers Squibb, 9, Fibrogen, 9, Gilead Sciences, 9, NIH, 2, Nitto, 9, Promedior, 9, Revistan, 9, Roche, 9, Roche/Genentech, 9, Roche-Genentech, 5, Sanofi, 9, Veracyte, 9; I. Rodriguez-Pinto, None; I. Rosas, None; J. Seibold, Boehringer Ingelheim, 5, Camurus AB, 5, Octapharma, 5, Corbus, 5, Bayer, 5, Indalo, 5, Blade, 5, Mitsubishi Tanabe Pharma, 5, Eicos Sciences, 5, Athersys, 4, Pacific Therapeutics, 4, BriaCell, 4; V. Steen, Boehringer Ingelheim, 5, Corbus, 5, 9, CSL, 5, 9, CSL Behring, 2, 5, DSMB, 5, 9, Galapagos, 5, 9; V. Strand, Abbvie, 5, AbbVie, 5, Amgen, 5, Amgen, Abbvie, Bayer, BMS, Boehringer Ingelheim, Celltrion, Janssen, Lilly, Merck, Novartis, Pfizer, Regeneron, Samsung, Sandoz, Sanofi, UCB, 5, AstraZeneca, 5, AURA, 8, Bayer, 5, BMS, 5, Boehringer Ingelheim, 5, Celgene, 5, Celltrion, 5, Cleveland Clinic, 8, CORRONA, 5, Crescendo, 5, Crescendo Bioscience, 5, Eli Lilly, 5, EMD Serono, 5, Genentech, 5, GlaxoSmithKline, 5, GSK, 5, Horizon, 5, Inmedix, 5, Janssen, 5, Kezar, 5, Lilly, 5, Merck, 5, NACCME, 8, Novartis, 5, Pfizer, 5, Purdue, 8, RA Forum, 8, RAN, 8, Regeneron, 5, Roche, 5, Samsung, 5, Sandoz, 5, Sanofi, 5, Servier, 5, Setpoint, 5, SLRA, 8, UCB, 5, Up to Date, 7, Washington University, 8, WIR, 8, WRA, 8; E. Volkmann, Boehringer Ingelheim, 5, Boehringer-Ingelheim, 5, Pfizer, 1, 4; D. Vummidi, None; S. Walsh, None; D. Zoz, Boehringer Ingelheim, 3, Boehringer Ingelheim Pharmaceuticals, 3; A. Wells, None; D. Khanna, Acceleron, 5, 8, Acceleron Pharma, 5, Actelion, 5, 8, Actelion Pharmaceuticals, 5, Astra Zeneca, 5, Bayer, 2, 5, 8, Behring, 5, Blade, 5, Blade Therapeutics, 5, 8, Blade therapeutics, 5, BMS, 2, 5, 8, Boehringer Ingelham, 5, Boehringer Ingelheim, 5, 8, Boehringer-Ingelheim, 5, Bristol Myers Squibb, 2, 5, Bristol-Myers Squibb, 2, 5, Celegene, 5, Celgene, 5, 8, ChemomAB, 5, ChemomAb, 5, CiviBioPharma, Inc., 3, Corbus, 5, Corobus, 5, Corpus, 5, CSL Behring, 5, 8, Curizon, 5, Curzion, 5, Cytori, 5, 8, Eicos, 4, Eicos Sciences, 4, Eicos Sciences, Inc, 4, Eicos Sciences, Inc/ CiviBioPharma, Inc, 1, 4, Eicos Sciences, Inc/ CiviBioPharma, Inc., 1, Eicos, Inc, 4, Eicos, Inc., 5, 8, Eicos, INC., 4, Galapagos, 5, Genentech, 5, Genentech/Roche, 5, GlaxoSmithKline, 5, GSK, 5, Horizon, 2, 5, Mitsubishi Tanabe Pharma, 5, Mitsubishi Tanabe Pharma Dev America, 5, Mitsubishi Tanabe Pharma Development America, 5, Mitsubishi Tanabi, 5, NIH K24 and R01, 2, NIH / NIAMS K24 AR-063120, 2, NIH/NIAMS R01& K24, 2, Pfizer, 2, 5, Sanofi, 5, Sanofi Aventis, 5, Sanofi-Aventis, 5, 8, Sanofi-Aventis/Genzyme, 5, UCB, 5, UCB Pharma, 5.

To cite this abstract in AMA style:

Roofeh D, Brown K, Tashkin D, Assassi S, Barratt S, Bernstein E, Bhatt N, Chung L, Collard H, Conway R, Dellaripa P, Denton C, Distler O, Domsic R, Doyle T, Garcha P, Gupta N, Hoffmann-Vold A, Hsu V, Ingegnoli F, Johannson K, Kahaleh B, Kawano-Dourado L, Kazerooni E, Khanna S, Korsten P, Lin C, Maher T, Mathai S, Martinez F, Matteson E, Nagaraja V, Oddis C, Ovalles-Bonilla J, Pauling J, Raghu G, Rodriguez-Pinto I, Rosas I, Seibold J, Steen V, Strand V, Volkmann E, Vummidi D, Walsh S, Zoz D, Wells A, Khanna D. Subsets in Systemic Sclerosis-ILD: Working Towards Consensus-Based Definitions [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/subsets-in-systemic-sclerosis-ild-working-towards-consensus-based-definitions/. Accessed January 30, 2023.
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/subsets-in-systemic-sclerosis-ild-working-towards-consensus-based-definitions/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences